Mallinckrodt PLC (MNK) Shares Sold by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado reduced its position in Mallinckrodt PLC (NYSE:MNK) by 19.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,145 shares of the company’s stock after selling 3,589 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Mallinckrodt were worth $283,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. NuWave Investment Management LLC raised its position in Mallinckrodt by 5,538.7% during the first quarter. NuWave Investment Management LLC now owns 15,168 shares of the company’s stock valued at $218,000 after purchasing an additional 14,899 shares during the period. Alps Advisors Inc. raised its position in Mallinckrodt by 160.5% during the first quarter. Alps Advisors Inc. now owns 27,751 shares of the company’s stock valued at $402,000 after purchasing an additional 17,099 shares during the period. New York State Teachers Retirement System raised its position in Mallinckrodt by 5.3% during the first quarter. New York State Teachers Retirement System now owns 190,501 shares of the company’s stock valued at $2,758,000 after purchasing an additional 9,673 shares during the period. SG Americas Securities LLC raised its position in Mallinckrodt by 131.2% during the first quarter. SG Americas Securities LLC now owns 352,854 shares of the company’s stock valued at $5,109,000 after purchasing an additional 200,242 shares during the period. Finally, Bronfman E.L. Rothschild L.P. raised its position in Mallinckrodt by 11,188.0% during the first quarter. Bronfman E.L. Rothschild L.P. now owns 10,385 shares of the company’s stock valued at $150,000 after purchasing an additional 10,293 shares during the period.

In other news, insider Mark Trudeau acquired 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 16th. The shares were bought at an average price of $15.54 per share, with a total value of $46,620.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.80% of the company’s stock.

A number of equities research analysts have issued reports on the company. Cantor Fitzgerald restated a “buy” rating and set a $42.00 price objective on shares of Mallinckrodt in a research report on Tuesday, August 7th. Piper Jaffray Companies restated a “buy” rating and set a $39.00 price objective on shares of Mallinckrodt in a research report on Wednesday. Stifel Nicolaus upped their price objective on Mallinckrodt from $18.00 to $30.00 and gave the company a “hold” rating in a research report on Wednesday. Raymond James downgraded Mallinckrodt from an “outperform” rating to a “market perform” rating and set a $58.00 price objective on the stock. in a research report on Wednesday. They noted that the move was a valuation call. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $37.00 target price on shares of Mallinckrodt in a research note on Tuesday, August 7th. Three investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $30.95.

Mallinckrodt opened at $31.10 on Friday, according to MarketBeat Ratings. The company has a market cap of $2.55 billion, a PE ratio of 4.15, a price-to-earnings-growth ratio of 0.48 and a beta of 1.36. Mallinckrodt PLC has a one year low of $11.65 and a one year high of $41.70. The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 0.98.

Mallinckrodt (NYSE:MNK) last released its earnings results on Tuesday, August 7th. The company reported $1.78 EPS for the quarter, beating analysts’ consensus estimates of $1.48 by $0.30. The firm had revenue of $631.70 million for the quarter, compared to analysts’ expectations of $621.15 million. Mallinckrodt had a return on equity of 10.39% and a net margin of 59.85%. equities research analysts predict that Mallinckrodt PLC will post 6.67 earnings per share for the current year.

Mallinckrodt Company Profile

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.

Read More: Why Dividend Stocks May Be Right for You

Want to see what other hedge funds are holding MNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mallinckrodt PLC (NYSE:MNK).

Institutional Ownership by Quarter for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply